TNF and uveitis: Adalimumab (ADA, anti-TNF drug) has been successfully used in the management of uveitis in patients with AS [81] and VISUAL I, II, and III clinical trials [82,83,84] have demonstrated efficacy and safety in non-anterior non-infectious, corticosteroid-refractory uveitis or in which corticosteroids cannot be used at acceptable doses.